Navigation Links
Varian Medical Systems Spotlights TrueBeam Treatment System for First Time in Europe at ESTRO 2010, September 12-16, Barcelona
Date:9/10/2010

BARCELONA, Spain, Sept. 10 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

TrueBeam uses a multitude of technical innovations to dynamically synchronize imaging, patient positioning, motion management, and treatment delivery.  Designed to be a best-in-class and versatile platform, TrueBeam can be used for all forms of advanced external-beam radiotherapy including image-guided radiotherapy and radiosurgery (IGRT and IGRS), intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and RapidArc® radiotherapy.  The product line includes TrueBeam STx, specially configured for advanced radiosurgery.

With its high intensity mode, TrueBeam can deliver doses at up to 2400 MU/min, more than twice as fast as any other machine for either radiotherapy or radiosurgery. Planning of such rapid treatments is fully supported in the latest version of Varian's Eclipse™ treatment planning system that will also be demonstrated on the Varian booth.

Also on display will be Varian's new Gated RapidArc capability, which enables the use of RapidArc technology in combination with respiratory gating – a process of turning the beam on and off in synchrony with the patient's breathing – during either radiotherapy or radiosurgery. This technology helps to improve the precision of treatment delivery by compensating for tumor motion. Gated RapidArc is available as an upgrade for Trilogy® and Clinac® iX accelerators.  

Varian's UNIQUE™ low energy medical linear accelerator for fast, affordable image-guided RapidArc IMRT treatments in international clinics, will also be on display on the Varian booth, along with the latest version of the company's ARIA® oncology information management software.

Varian's Particle Therapy group will be introducing its fully-integrated ProBeam™ proton therapy system at the show. The ProBeam system incorporates imaging, gating, robotic patient positioning, treatment planning and oncology information software to enhance treatment quality for patients and workflow efficiency for clinicians. Also on show will be the latest in Varian's range of brachytherapy afterloaders and software.

"Varian is at the forefront of technology advances that enable clinicians to benefit patients by delivering faster and more efficient treatments," says Rolf Staehelin, head of Varian's Oncology Systems marketing in Europe.  "With major introductions such as TrueBeam and Gated RapidArc and with a series of ancillary events that focus on the very latest in advanced radiotherapy treatment capabilities, we are looking forward to sharing our excitement about these developments with the radiation oncology community. All the innovations on display at ESTRO are clinically-viable and commercially available today."  

TrueBeam Spotlighted in Series of ESTRO Events

The world's first TrueBeam treatment took place at Zurich University Hospital in Switzerland in April and Professor Urs Luetolf, the hospital's head of radiation oncology, will be presenting his team's latest results at an Emerging Technologies Symposium at ESTRO on September 14th Professor Ben Slotman of VU University Medical Center in Amsterdam, Netherlands, will also be presenting, while Professor John Adler, Varian's chief of new clinical applications, will talk about 'The Future of Radiosurgery and Stereotactic Body Radiotherapy'.

Another highlight at ESTRO 2010 will be a TrueBeam Technologies Night at the Institut Catala d'Oncologia (ICO) in Barcelona, one of the first ten centers in Europe to be equipped with a TrueBeam system.  The device is currently being installed at ICO and will be clinical later this year. Professor Ferran Guedea, head of radiation oncology at ICO, will act as moderator at the Emerging Technologies Symposium.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
Breaking Medicine Technology:
(Date:2/5/2016)... Seattle, WA (PRWEB) , ... February 05, 2016 ... ... consulting firm, ranked #3 in the 2015 Best in KLAS: Software & Services ... The annual Best in KLAS report independently ranks vendor performance by healthcare ...
(Date:2/5/2016)... ... , ... Stuart Bentkover, MD, FACS is thrilled to announce the ... effective tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to ... has been approved by the Food and Drug Administration (FDA) as a safe and ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
Breaking Medicine News(10 mins):